The allegations against Purdue Pharma are focused on its marketing practices for OxyContin. In 2007, Purdue and three of its executives were fined $630 million for its misleading marketing campaign for OxyContin. The company and the executives had represented that OxyContin's extended-release formulary was less addictive than forms that required people to take pills several times per day. However, evidence was uncovered that showed that Purdue was aware of the addictive potential of OxyContin soon after it was approved by the FDA in the 1990s.[9] In the company's response to a lawsuit filed against it by the state of Alaska, Purdue Pharma argued that it was allowed to push OxyContin by the FDA rules that were written for its newer approved formulation of the drug. However, advocacy groups funded by Purdue helped the FDA to write the rules that the company has cited in its defense.[10]